Ferulic acid, a hydroxycinnamic
acid, is abundant in vegetables,
grains, and medicinal plants. Emerging evidence suggests that ferulic
acid may exert beneficial effects against colorectal cancer. However,
the anticancer activity of ferulic acid is relatively low, and its
metabolism after oral administration is largely unknown. In this study,
mimicking the enteric environment, human intestinal microflora and
commercial probiotics were used to metabolize ferulic acid to its
metabolites, and their anticancer activities were evaluated. Ferulic
acid can be biotransformed to 4-vinylguaiacol (2-methoxy-4-vinylphenol),
and the contents of ferulic acid and 4-vinylguaiacol in bio-transformed
extracts were determined by high-performance liquid chromatography
(HPLC). Using the chemotherapy-sensitive cell line HCT-116 and the
chemo-resistant cell line HT-29, the cell proliferation was determined
by the modified trichrome stain assay. The cell cycle and induction
of apoptosis were assayed using flow cytometry. HPLC data showed that
there was a marked transformation from ferulic acid to 4-vinylguaiacol,
and the conversion rates of intestinal microflora and four probiotics
were from 1.3 to 36.8%. Both ferulic acid and 4-vinylguaiacol possessed
dose- and time-related anticancer activities on the two cell lines,
while 4-vinylguaiacol showed more potent effects than ferulic acid.
Interestingly, 4-vinylguaiacol exhibited significantly higher antiproliferative
effects on the HT-29 cell line than that on HCT-116. The IC50 of the
metabolite 4-vinylguaiacol on HT-29 cells was 350 μM, 3.7-fold
higher than its parent compound. The potential of cancer cell growth
inhibition of 4-vinylguaiacol was mediated by cell cycle arrest at
the G1 phase and induction of apoptosis. Data from this study indicate
that the oral administration of ferulic acid offers a promising approach
to increase its anticancer activity through gut microbial conversion
to 4-vinylguaiacol, and the biotransformation could also be achieved
by selected commercial probiotics. 4-Vinylguaiacol is a potential
anticancer metabolite from ferulic acid for chemotherapy-resistant
colon cancer cells.